Draflazine

Drug Profile

Draflazine

Alternative Names: R 70380

Latest Information Update: 11 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen L.P.
  • Developer Janssen L.P.; Nonindustrial source
  • Class Antiplatelets; Piperazines
  • Mechanism of Action Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Belgium (Unknown route)
  • 11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Netherlands (Unknown route)
  • 11 Jun 2000 Discontinued-Preclinical for Ischaemic heart disorders in Norway (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top